HomeBUSINESS
BUSINESS

Trazenta-Jardiance Combo Filed in Japan: Lilly/Boehringer
(Oct.4.2017)

Nippon Boehringer Ingelheim has filed a new drug application in Japan for a fixed-dose combination drug of its sodium-glucose co-transporter-2 (SGLT-2) inhibitor Jardiance (empagliflozin) and dipeptidyl peptidase-4 (DPP-4) inhibitor Trazenta (linagliptin) ...
(LOG IN FOR FULL STORY)

News Calendar